Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study

被引:31
|
作者
Afif, Waqqas [1 ,2 ]
Sandborn, William J. [1 ,3 ]
Faubion, William A. [1 ]
Rahman, Meher [4 ]
Harmsen, Scott W. [5 ]
Zinsmeister, Alan R. [5 ]
Loftus, Edward V., Jr. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, Montreal, PQ, Canada
[3] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
[4] Mayo Clin Hlth Syst, Immanuel St Josephs Specialty Clin, Gastroenterol Sect, Mankato, MN USA
[5] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
lymphoma; immunosuppressive; anti-TNF-alpha; EPSTEIN-BARR-VIRUS; CROHNS-DISEASE; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; AZATHIOPRINE; THERAPY; INFLIXIMAB; IMMUNOSUPPRESSION; 6-MERCAPTOPURINE;
D O I
10.1097/MIB.0b013e318281325e
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD.Methods:Cases and controls were identified through a centralized diagnostic index. We identified 80 adult patients with IBD who developed lymphoma between 1980 and 2009. For each case, 2 controls were matched for subtype of IBD, geographic location, and length of follow-up. Conditional logistical regression was used to assess associations between risk factors and the development of lymphoma.Results:Sixty patients were males (75%) versus 77 controls (48%). Median age at index date was 59 years for cases and 42 years for controls. Twenty patients (25%) and 23 controls (14%) were receiving immunosuppressive medications at the index date. Four patients (5%) and 6 controls (4%) were receiving anti-tumor necrosis factor agents at the index date. In multiple variable analysis, age per decade (odds ratio, 1.83; 95% confidence interval, 1.37-2.43), male gender (odds ratio, 4.05; 95% confidence interval, 1.82-9.02) and immunosuppressive exposure at the index date (odds ratio, 4.20; 95% confidence interval, 1.35-13.11) were significantly associated with increased odds of developing lymphoma. Disease severity and use of anti-tumor necrosis factor agents were not independently associated with developing lymphoma. When testing was performed on patients exposed to immunosuppressive or anti-tumor necrosis factor medications, Epstein-Barr virus was identified 75% of the time.Conclusions:In this case-control study, increasing age, male gender, and use of immunosuppressive medications were associated with an increased risk of lymphoma in patients with IBD.
引用
下载
收藏
页码:1384 / 1389
页数:6
相关论文
共 50 条
  • [1] Risk Factors for Lymphoma in Patients With Inflammatory Bowel Disease: A Case-Control Study
    Afif, Waqqas
    Sandborn, William J.
    Faubion, William A.
    Rahman, Meher
    Harmsen, William S.
    Zinsmeister, Alan R.
    Loftus, Edward V.
    GASTROENTEROLOGY, 2011, 140 (05) : S42 - S42
  • [2] A case-control study on risk factors in Inflammatory bowel disease
    Zhu Zhenhua
    Zeng Zhirong
    Peng Xiabiao
    Peng Lin
    Hao Yuantao
    Qian Jiaming
    Chien, Ng Siew
    Chen Minhu
    Hu Pinjin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 145 - 145
  • [3] Risk factors for active tuberculosis in patients with inflammatory bowel disease: A case-control study
    Riestra, Sabino
    De Francisco, Ruth
    Arias-Guillen, Miguel
    Saro, Cristina
    Garcia-Alvarado, Maria
    Duque, Jose Maria
    Munoz, Fernando
    Blanco, Lorena
    Castano, Olegario
    Perez-Martinez, Isabel
    Martinez-Camblor, Pablo
    Perez-Hernandez, Dolores
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] Risk Factors for Active Tuberculosis in Patients With Inflammatory Bowel Disease: A Case-Control Study
    Riestra, Sabino
    de Francisco, Ruth
    Arias-Guillen, Miguel
    Saro, Cristina
    Garcia-Alvarado, Maria
    Duque, Jose Maria
    Munoz, Fernando
    Blanco, Lorena
    Castano, Olegario
    Perez-Martinez, Isabel
    Martinez-Camblor, Pablo
    Perez-Hernandez, Dolores
    GASTROENTEROLOGY, 2015, 148 (04) : S461 - S461
  • [5] Risk factors for active tuberculosis in patients with inflammatory bowel disease: A case-control study
    Riestra, S.
    de Francisco, R.
    Arias-Guillen, M.
    Saro, C.
    Garcia-Alvarado, M.
    Duque, J. M.
    Blanco, L.
    Castano, O.
    Munoz, F.
    Perez-Martinez, I.
    Martinez-Camblor, P.
    Perez-Hernandez, D.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S124 - S124
  • [6] Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease
    Shan-Shan Gong
    Yi-Hong Fan
    Qing-Qing Han
    Bin Lv
    Yi Xu
    World Journal of Gastroenterology, 2019, (18) : 2240 - 2250
  • [7] Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study
    Parente, Fabrizio
    Pastore, Luca
    Bargiggia, Stefano
    Cucino, Claudia
    Greco, Salvatore
    Molteni, Mirko
    Ardizzone, Sandro
    Porro, Gabriele Bianchi
    Sampietro, Gianluca M.
    Giorgi, Riccardo
    Moretti, Roberto
    Gallus, Silvano
    HEPATOLOGY, 2007, 45 (05) : 1267 - 1274
  • [8] Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease
    Gong, Shan-Shan
    Fan, Yi-Hong
    Han, Qing-Qing
    Lv, Bin
    Xu, Yi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (18) : 2240 - 2250
  • [9] Genetic risk factors in patients with inflammatory bowel disease and vascular complications: Case-control study
    Koutroubakis, I. E.
    Sfiridoki, A.
    Tsiolakidou, G.
    Theodoropoulou, A.
    Livadiotaki, A.
    Paspatis, G.
    Kouroumalis, E. A.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (04) : 410 - 415
  • [10] Dietary risk factors for inflammatory bowel disease in Shanghai: A case-control study
    Mi, Lin
    Zhang, Chen
    Yu, Xiao-feng
    Zou, Jian
    Yu, Yang
    Bao, Zhi-Jun
    ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2022, 31 (03) : 405 - 414